Cyclooxygenase Inhibition and Cardiovascular Risk

This publication has 67 references indexed in Scilit:

• Inflammation, Atherosclerosis, and Coronary Artery Disease
  New England Journal of Medicine, 2005
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
  New England Journal of Medicine, 2005
• The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus
  Archives of internal medicine (1960), 2005
• Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension
  Hypertension, 2003
• Dual Functionality of Cyclooxygenase-2 as a Regulator of Tumor Necrosis Factor–Mediated G ₁ Shortening and Nitric Oxide–Mediated Inhibition of Vascular Smooth Muscle Cell Proliferation
  Circulation, 2003
• Effects of low‐dose aspirin on endothelial function in hypertensive patients
  Clinical Cardiology, 2001
• Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
  The American Journal of Pathology, 1999
• Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
  New England Journal of Medicine, 1984
• Differential Inhibition by Aspirin of Vascular and Platelet Prostaglandin Synthesis in Atherosclerotic Patients
  New England Journal of Medicine, 1983